TABLE 2.
Head-to-Head Comparison of SUVmax Between [18F]FAPI-74 PET and [18F]FDG PET
| [18F]FAPI-74 PET | [18F]FDG PET | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer type | State | Primary lesion | LN metastasis (1) | LN metastasis (2) | Other metastases | Location | Primary lesion | LN metastasis (1) | LN metastasis (2) | Other metastases | Location |
| Breast cancer | Before surgery | 25.3 | 10.1 | 6.9 | 2.6 | ||||||
| Breast cancer | Before treatment | 22.1 | 6.3 | 5.8* | 7.3 | 1.7 | ND (1.0) | ||||
| Breast cancer (case shown in Fig. 4) | Before treatment | 19.6 | 23.3 | 11.9* | 13.0 | 8.5 | 7.4 | ||||
| Breast cancer | Recurrence | 11.0 | 10.9* | 12.8, 12.5 | Liver | 3.8 | 2.5 | 8.0, 8.4 | Liver | ||
| Esophageal cancer | Before treatment | 10.0 | 7.2 | ||||||||
| Gastric cancer | Before treatment | 5.0 | 2.2 | ||||||||
| Gastric cancer | After NAC | 8.2 | 5.5 | ||||||||
| Gastric cancer | After NAC | ND | 5.8 | ND | 9.8 | ||||||
| Gastric cancer | After NAC | 3.4 | 3.1 | ||||||||
| Gastric cancer | After NAC | 7.2 | 10.4 | ||||||||
| Lung cancer | Before surgery | 15.4 | 13.3 | ||||||||
| Lung cancer | Before surgery | 6.4 | 4.7 | ||||||||
| Lung cancer | Before surgery | 5.1 | 2.5 | ||||||||
| Lung cancer (case shown in Fig. 5) | Before surgery | 2.5 | 1.2 | ||||||||
| Lung cancer | Before surgery | 11.8 | 3.5 | 14.9 | 4.9 | ||||||
| Head and neck | Before treatment | 14.8 | 11.5 | 8.9* | 15.1 | 7 | 4.4 | ||||
| Pancreatic cancer | Before treatment | 13.2 | 3.1 | ||||||||
| Pancreatic cancer (case shown in Fig. 3) | Before treatment | 9.4 | 5.4 | 6.5* | 7.5, 5.3 | Peritoneum | 3.2 | ND (2.3) | ND (1.5) | ND (2.0, 1.8) | Peritoneum |
| Pancreatic cancer | Recurrence | 9.4 | 10.6 | 5.0* | 4.6 | Peritoneum | 4.5 | 5.5 | 1.8 | ND (1.2) | Peritoneum |
| Thymoma (type B3) | Recurrence | ND (0.6) | Pleura | ND (0.7) | Pleura | ||||||
*
Number of detected LN metastases is more than 3, and 2 major sites are shown here.
ND = not detected; NAC = neoadjuvant chemotherapy.